Rockwell Medical (RMTI) Fundamental Analysis: Revenue, Earnings & Valuation

7.17 / 10

Outperform

Fundamentals are rated Outperform with a 7.2/10 profile. Strengths include strong accounts‑receivable turnover (6.13) and interest coverage (15.64), while concerns arise from a -33.7% YoY revenue decline and negative income‑tax ratio. Overall, the company shows a solid but mixed financial foundation.

Analysis Checks(7/10)

Revenue-MV

Value0.51

Score2/3

Weight31.85%

1M Return6.87%

Total operating revenue (YoY growth rate %)

Value-33.73

Score1/3

Weight-4.58%

1M Return-1.40%

Inventory turnover ratio

Value8.85

Score3/3

Weight-2.13%

1M Return-0.67%

Accounts receivable turnover ratio

Value6.13

Score2/3

Weight-2.11%

1M Return-0.65%

PB-ROE

Value-0.35

Score3/3

Weight54.33%

1M Return12.56%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-4.80%

1M Return-1.54%

Fixed assets turnover ratio

Value9.48

Score3/3

Weight2.81%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-2.38%

1M Return-0.73%

Cost of sales ratio (%)

Value84.65

Score1/3

Weight-20.10%

1M Return-7.47%

Asset-MV

Value-0.48

Score2/3

Weight47.11%

1M Return9.91%

Is RMTI undervalued or overvalued?

RMTI scores 7.17/10 on fundamentals and holds a Discounted valuation at present. Backed by its -13.68% ROE, -7.30% net margin, -6.50 P/E ratio, 0.97 P/B ratio, and -350.00% earnings growth, these metrics solidify its Outperform investment rating.